<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016716</url>
  </required_header>
  <id_info>
    <org_study_id>20120156</org_study_id>
    <secondary_id>2013-000434-35</secondary_id>
    <nct_id>NCT02016716</nct_id>
  </id_info>
  <brief_title>A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone
      mineral density (BMD) in postmenopausal women with osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon confirmation of eligibility, participants were randomized in a 22:5:22:5 ratio to the
      following treatment groups:

        -  Romosozumab 90 mg/mL

        -  Placebo 90 mg/mL

        -  Romosozumab 70 mg/mL

        -  Placebo 70 mg/mL

      After completing a 6-month treatment period, participants entered a 3-month follow-up period
      with an end of study (EOS) at month 9.

      For the analysis of efficacy endpoints, the 2 placebo groups were combined into a single
      placebo group. For safety analyses, the data for placebo were presented separately for each
      group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2013</start_date>
  <completion_date type="Actual">December 8, 2014</completion_date>
  <primary_completion_date type="Actual">September 8, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the percent change from baseline in DXA BMD at the lumbar spine (noninferiority)</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint is the percent change from baseline in DXA BMD at the lumbar spine (noninferiority)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percent change from baseline in DXA BMD at the total hip</measure>
    <time_frame>Month 6</time_frame>
    <description>percent change from baseline in DXA BMD at the total hip • percent change from baseline in DXA BMD at the femoral neck • percent change from baseline in BTMs P1NP and CTX</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Romosozumab 90 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 210 mg romosozumab monthly, administered as 2 subcutaneous (SC) 1.17 mL injections of a 90 mg/mL solution, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 90 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received matching placebo administered as 2 subcutaneous injections of 1.17 mL every month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab 70 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 210 mg romosozumab monthly, administered as 3 subcutaneous 1.0 mL injections of a 70 mg/mL solution, for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 70 mg/mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo administered as 3 subcutaneous injections of 1.0 mL every month for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab 90 mg/mL</intervention_name>
    <description>Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).</description>
    <arm_group_label>Romosozumab 90 mg/mL</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>EVENITY™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 90 mg/mL</intervention_name>
    <description>Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.</description>
    <arm_group_label>Placebo 90 mg/mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab 70 mg/mL</intervention_name>
    <description>Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.</description>
    <arm_group_label>Romosozumab 70 mg/mL</arm_group_label>
    <other_name>AMG 785</other_name>
    <other_name>EVENITY™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 70 mg/mL</intervention_name>
    <description>Placebo administered as 3 SC injections with the 1.0 mL glass PFS.</description>
    <arm_group_label>Placebo 70 mg/mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Postmenopausal women with osteoporosis at high risk for fracture defined as

          -  BMD T-score ≤ -2.50 at the lumbar spine, total hip, or femoral neck AND

          -  a history of fragility fracture or at least 2 other risk factors

        Exclusion Criteria:

          -  BMD T score &lt; -3.50 at the total hip or femoral neck.

          -  History of hip fracture.

          -  History of metabolic or bone disease (except osteoporosis).

          -  Use of agents affecting bone metabolism.

          -  Vitamin D insufficiency.

          -  History of solid organ or bone marrow transplants.

          -  Hyper- or hypocalcemia.

          -  Hyper- or hypothyroidism.

          -  Hyper- or hypoparathyroidism.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klatovy</city>
        <zip>339 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <zip>44-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <disposition_first_submitted>June 22, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>June 22, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 15, 2015</disposition_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postmenopausal Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

